Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Clearmind Medicine Inc. - Common Shares (NQ:CMND)

1.020 -0.081 (-7.32%)
Streaming Delayed Price Updated: 9:47 AM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clearmind Medicine Inc. - Common Shares

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Dow Jumps Over 200 Points; US Producer Prices Rise In August
U.S. stocks traded higher this morning, following the release of PPI data. Following the market opening Thursday, the Dow traded up 0.71% to 34,820.58 while the NASDAQ rose 0.27% to 13,849.49. The S&P... 
Via Benzinga
Topics Stocks
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering
From Clearmind Medicine Inc.
Via GlobeNewswire
Why Novo Integrated Sciences Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 43.3% to $1.29 in pre-market trading. 
Via Benzinga
Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More
Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification 
Via Benzinga
Topics Artificial Intelligence
Nasdaq Grants SpiSparc, Ltd. Extension To Maintain Listing: +600% Bid Price Surge Needed
Specialty clinical-stage biopharma company SciSparc Ltd. (NASDAQ: SPRC) has received a Nasdaq notice granting the company an additional 180-day compliance period until March 4 to regain compliance with... 
Via Benzinga
Johns Hopkins Will Work With Clearmind On Alcohol Addiction Research Program
Israeli psychedelics biotech Clearmind Medicine (NASDAQ: CMND) has inked a research agreement with Johns Hopkins University School of Medicine (JHU) to conduct the first-in-human Phase I/IIa clinical... 
Via Benzinga
Clearmind Medicine Announces Clinical Research Collaboration with Johns Hopkins University to Evaluate CMND-100 in Patients with Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
From SciSparc Ltd
Via GlobeNewswire
EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio
Clearmind Medicine Inc (NASDAQ: CMND) has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (USPTO) as part of... 
Via Benzinga
Clearmind Medicine Announces Share-Based Payment for the Company's Consultants
From Clearmind Medicine Inc.
Via GlobeNewswire
Dr. Fatima Cody Stanford, Associate Professor of Medicine and Pediatrics at Harvard Medical School, Joins Clearmind Medicine's Scientific Advisory Board
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
From Clearmind Medicine Inc.
Via GlobeNewswire
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
From SciSparc Ltd
Via GlobeNewswire
Exclusive: Clearmind And SciSparc To Conduct Study Evaluating Psychedelics And CannAmide Based Drug For Treatment Of Obesity And Metabolic Syndrome
Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:CMND) (FSE:CWY) announced that as part of the company's ongoing collaboration with SciSparc Ltd. 
Via Benzinga
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
From Clearmind Medicine Inc.
Via GlobeNewswire
MEAI Compound's First Clinical Trial In US, Clearmind Enters NASDAQ Compliance Period
Clearmind Medicine Inc. (NASDAQ: CMND), an Israel-based biotech company advancing the clinical stage for an MEAI-based compound targeting Alcohol Use Disorder (AUD,) has selected Yale School of... 
Via Benzinga
Clearmind Medicine Announces First US Site for its Phase I/IIa Clinical Trial Evaluating CMND-100 in Patients with Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
From Clearmind Medicine Inc.
Via GlobeNewswire
Why DXC Technology Shares Are Trading Lower By Around 5%; Here Are 20 Stocks Moving Premarket
Gainers Monogram Orthopaedics Inc. (NASDAQ: MGRM) shares surged 163.7% to $30.98 in pre-market trading after jumping 62% on Thursday. Monogram Orthopaedics raised $17,216,147 through the sale of... 
Via Benzinga
Clearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
From Clearmind Medicine Inc.
Via GlobeNewswire
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
Benzinga Pro's Top 5 Stocks To Watch For Friday, May 12, 2023: CMCSA, KR, ON, TSVT, CMND
Comcast (CMCSA) - The parent company of NBCUniversal. One of Friday's most-discussed stories stemmed from a tweet by Elon Musk he had found a new exec to file the chief exec role at Twitter. 
Via Benzinga
Clearmind Medicine Announces IRB Approval to Conduct Clinical Trial on Alcohol Use Disorder
From Clearmind Medicine Inc.
Via GlobeNewswire
EXCLUSIVE: Clearmind Medicine Secures Approval To Launch Clinical Trial For Alcohol Addiction Treatment
Clearmind Medicine Inc. 
Via Benzinga
Clearmind Medicine Retains Crescendo Communications LLC. for Investor Relations and Announces Granting of Stock and Warrants
From Clearmind Medicine Inc.
Via GlobeNewswire
Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
EXCLUSIVE: AMA Moves Toward Psychedelic Therapy Reimbursement, Filing A Gap In Regulations 
Via Benzinga
Clearmind Medicine Strengthens Scientific Advisory Board with Appointment of Prof. Joseph Tam
From Clearmind Medicine Inc.
Via GlobeNewswire
Next-Gen Israeli Psychedelics Company Gears Up For Trial Targeting Alcohol Addiction
Alcohol Use Disorder (AUD) is one of the top-targeted health issues by biopharma companies. In the case of Clearmind Medicine (NASDAQ: CMND), the Israel-based company is going at it through its... 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.